• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer

    12/2/20 8:00:00 AM ET
    $SNY
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNY alert in real time by email

    CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed as Chief Human Resources Officer (CHRO). As CHRO, Mr. Rosin will provide strategic enterprise counsel and leadership, both as a member of Wave’s Executive Team and by leading the human resources function.

    “Jonathan is an accomplished leader with the breadth of human resources experience necessary to help guide Wave as we prepare to support five programs in clinical trials in 2021, as well as advance a robust preclinical portfolio and our novel discovery and drug development platform,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. “Wave is growing and having Jonathan at the helm of our HR function, as well as on our leadership team, will ensure that we continue to build a world-class organization, scale smartly, and maintain Wave’s special culture.”

    Mr. Rosin joins Wave with more than 25 years of experience in human resources, organization development, talent strategy, and leadership and team development. Prior to joining Wave, Mr. Rosin spent seven years as CHRO at Ironwood Pharmaceuticals where he served as a member of the executive operating committee. During his tenure at Ironwood, he was instrumental in building organizational capabilities and shaping the culture to support the company’s transition into a fully integrated biotechnology company, and continuously sought to upgrade Ironwood’s capabilities and focus on execution. Prior to joining Ironwood, he held human resources roles of increasing responsibility at Sanofi Genzyme and Fidelity Investments, among others. He has also consulted globally across industries as well as with multiple biotechnology companies to help build high-performing teams and to provide leadership coaching.

    “I am thrilled to be joining Wave at such an exciting and promising time, and to have the opportunity to partner with this exceptional team and individuals across the company,” said Mr. Rosin. “It is clear to me that Wave has developed and nurtured a unique and compelling culture that values innovation, inclusion, and making an impact on behalf of patients. I look forward to working with the team to continue transforming Wave’s vision into reality.”

    In connection with Mr. Rosin joining Wave, he received a share option award to purchase 53,000 ordinary shares of Wave and 27,000 restricted share units (RSU). The option and RSU were approved by Wave’s Compensation Committee and were granted to Mr. Rosin on December 1, 2020 outside of the Wave Life Sciences Ltd. 2014 Equity Incentive Plan, as amended, as an inducement material to Mr. Rosin’s commencing employment with Wave, in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option has an exercise price of $8.95 per share, the closing price on the grant date, and vests over four years with 25% vesting on December 1, 2021 and the remainder vesting in equal quarterly installments over the following three years. The RSU vests over four years in equal annual installments beginning on the first anniversary of the grant date.

    About Wave Life Sciences
    Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

    Forward-Looking Statements
    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Mr. Rosin’s leadership and human resources experience guiding the company as it advances its clinical trials, preclinical portfolio and discovery and drug development platform; and beliefs that Mr. Rosin’s ability will help the growth of the company and its culture. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those discussed in these statements. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

    Investor Contact:
    Graham Morrell
    781-686-9600
    [email protected]

    Media Contact:
    Alicia Suter
    617-949-4817
    [email protected]


    Get the next $SNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNY
    $WVE

    CompanyDatePrice TargetRatingAnalyst
    Wave Life Sciences Ltd.
    $WVE
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    Sanofi
    $SNY
    4/15/2025$65.00Outperform
    Exane BNP Paribas
    Wave Life Sciences Ltd.
    $WVE
    4/8/2025$18.00Outperform
    Wedbush
    Sanofi
    $SNY
    3/21/2025$65.00Neutral
    Goldman
    Wave Life Sciences Ltd.
    $WVE
    2/25/2025$26.00Buy
    Jefferies
    Sanofi
    $SNY
    1/30/2025Sell → Hold
    Deutsche Bank
    Wave Life Sciences Ltd.
    $WVE
    10/16/2024$22.00Outperform → Strong Buy
    Raymond James
    Wave Life Sciences Ltd.
    $WVE
    9/27/2024$10.00 → $13.00Overweight
    JP Morgan
    More analyst ratings

    $SNY
    $WVE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

      Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon 53 amenable DMD including statistically significant and clinically meaningful improvement i

      5/8/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company's first quarter 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call by di

      5/1/25 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

      Believes Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on Heplisav Could Result in More than $1 Billion in Cash Generation by 2030 – More than Dynavax's Current Enterprise Value Sees Shareholder Representation on Board as Necessary to Restore Investor Confidence in Dynavax and Prevent Strategic Blunders Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDA

      4/21/25 4:05:00 PM ET
      $DVAX
      $MRNA
      $SNY
      $TARS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $SNY
    $WVE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

      For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

      3/28/25 10:17:55 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

      For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

      2/14/25 3:00:13 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

      Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

      11/4/24 4:49:34 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    $WVE
    Leadership Updates

    Live Leadership Updates

    See more
    • I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

      6/6/24 7:00:00 AM ET
      $AZN
      $IMAB
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

      CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK

      5/9/24 7:00:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi Bridging the Gap between the Homeless and Society via Futsal

      Sanofi hosted the founding ceremony of the homeless futsal club ‘Dream' and organized a friendly match as a part of the Helping Hands program Sanofi employees and ‘Dream' members interacted through the friendly match Sanofi has carried out social responsibility activities targeting the homeless and housing vulnerable groups since 2011 Sanofi in Korea[1], the Korean subsidiaries of the global healthcare company Sanofi, hosted the founding ceremony of the homeless futsal club ‘Dream' together with Dalpengyee, a nonprofit organization, to promote self-sufficiency among the homeless. At the founding ceremony of the ‘Dream', held in Seongsu-dong, Seoul on the 17th, the club's first game

      10/17/23 9:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    $WVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Gsk Plc bought $22,335,440 worth of Ordinary Shares (2,791,930 units at $8.00) (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      10/1/24 5:54:39 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gsk Plc bought $16,500,000 worth of Ordinary Shares (3,300,000 units at $5.00) (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      1/30/24 4:39:08 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ra Capital Management, L.P. bought $5,000,000 worth of shares (1,000,000 units at $5.00) (SEC Form 4) (Amendment)

      4/A - Wave Life Sciences Ltd. (0001631574) (Issuer)

      1/17/24 7:06:57 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    $WVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Henry Christian O sold $102,574 worth of Ordinary Shares (10,500 units at $9.77) and exercised 10,500 units of Ordinary Shares at a strike of $9.13 (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/21/25 9:00:05 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Bolno Paul exercised 169,025 units of Ordinary Shares at a strike of $2.48 and sold $1,617,569 worth of Ordinary Shares (169,025 units at $9.57) (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/7/25 9:05:03 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Verdine Gregory L. exercised 266,402 units of Ordinary Shares at a strike of $2.48, increasing direct ownership by 577% to 312,517 units (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/7/25 9:00:05 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    $WVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      11/12/24 4:30:35 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      11/12/24 9:34:18 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sanofi

      SC 13G/A - Sanofi (0001121404) (Subject)

      11/7/24 2:49:36 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    $WVE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Wave Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $10.00

      4/29/25 8:13:21 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exane BNP Paribas initiated coverage on Sanofi with a new price target

      Exane BNP Paribas initiated coverage of Sanofi with a rating of Outperform and set a new price target of $65.00

      4/15/25 12:40:46 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Wave Life Sciences with a new price target

      Wedbush initiated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $18.00

      4/8/25 9:33:34 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    $WVE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Wave Life Sciences Ltd.

      10-Q - Wave Life Sciences Ltd. (0001631574) (Filer)

      5/8/25 7:45:16 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Wave Life Sciences Ltd.

      8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

      5/8/25 7:36:06 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 13F-HR filed by Sanofi

      13F-HR - Sanofi (0001121404) (Filer)

      5/6/25 6:15:02 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    $WVE
    Financials

    Live finance-specific insights

    See more
    • Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

      Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon 53 amenable DMD including statistically significant and clinically meaningful improvement i

      5/8/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company's first quarter 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call by di

      5/1/25 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

      Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA First-ever demonstration of substantial improvements in muscle health with exon skipping – statistically significant reduction in fibrosis driven by decreases in inflammation and necrosis, coupled with transition from regenerative to mature muscle; decreases in creatine kinase and circulating inflammatory biomarkers Dystrophin expression stabilized between 24 and 48 weeks and averaged 7.8%, with 88% o

      3/26/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care